Maria Pagano
Reggio Nell'emilia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).
Journal: The oncologist
Published: February 11, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.
Journal: Cancer
Published: December 16, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.
Journal: The oncologist
Published: September 19, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 11, 2025
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives.
Journal: Molecular diagnosis & therapy
Published: October 28, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 08, 2024
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.
Journal: Diagnostics (Basel, Switzerland)
Published: March 25, 2024
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: May 30, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 21, 2022
Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation.
Journal: Frontiers in nutrition
Published: July 14, 2022
Last Updated: 09/26/2026